Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CAPR

Capricor Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CAPR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:33 UTC.

What Capricor Therapeutics, Inc. does

Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for treating Duchenne muscular dystrophy and other diseases with significant unmet medical need. The company's lead product candidate, Deramiocel, is a cell therapy made from cardiosphere-derived cells designed to slow disease progression through immunomodulatory and anti-inflammatory mechanisms, and its Biologics License Application is currently under review by the FDA.

Summarized from Capricor Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-27.82%

Revenue, margins & earnings

FY2021: net loss $20M on revenue $244,898$244,898FY2021FY2022: net loss $29M on revenue $3M$3MFY2022FY2023: net loss $22M on revenue $25M$25MFY2023FY2024: net loss $40M on revenue $22M$22MFY2024
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-29
Most recent filed transactions — June 2026:
  • 2026-06-29EVP, GENERAL COUNSELStock Option (Right to Buy)Option exercise-24,100—
  • 2026-06-29EVP, GENERAL COUNSELOption exercise24,100$76.6K
  • 2026-06-29CHIEF FINANCIAL OFFICERStock Option (Right to Buy)Option exercise-24,100—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Capricor Therapeutics, Inc. do?

Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for treating Duchenne muscular dystrophy and other diseases with significant unmet medical need.

When did CAPR last file with the SEC?

Capricor Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:33 UTC. This page is also available as JSON at /api/data?ticker=CAPR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CAPR and 5,000+ tickers.

Create a free account — keep CAPR
For your agent
GET /api/data?ticker=CAPR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt